Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2023-10-18 Call Transcript
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于召开2023年半年度暨第三季度业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement from a company about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2023 half-year and third quarter results. It provides the date, time, location, and participation instructions for the meeting but does not contain any actual financial data or detailed financial statements. The document is short (1514 characters) and serves to inform investors about the event rather than presenting the financial results themselves. According to the classification rules, such announcements about upcoming earnings calls or explanation meetings are best classified as Call Transcript (CT) if they contain the transcript, or if they are announcements of the meeting, they fall under Regulatory Filings (RNS). However, since this is specifically about an earnings explanation meeting (业绩说明会), which is a type of earnings call, and the document is about the meeting notice and participation details, the best fit is Call Transcript (CT) category as it relates to the earnings call event. Confidence is high because the document clearly states it is about the earnings explanation meeting and investor Q&A session.
2023-10-18 Chinese
迈威生物自愿披露关于2个品种在2023年欧洲肿瘤内科学会（ESMO）报告数据及其最新进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei Biotech about clinical trial data and latest progress of two drug candidates reported at the 2023 European Society for Medical Oncology (ESMO) conference. It contains detailed clinical trial results, safety data, and development updates. The document is an announcement of clinical data and progress rather than a full financial report or regulatory filing. It is not an earnings release, annual report, or interim report. It is also not a presentation or call transcript. The document is a regulatory announcement providing important clinical data updates to investors, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories and is a formal disclosure to the market.
2023-10-16 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2023年半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023 Half-Year Continuous Supervision Tracking Report" by Haitong Securities for Maiwei (Shanghai) Biotechnology Co., Ltd. It covers the period January to June 2023 and details the ongoing supervision activities by the sponsor institution as required by Chinese securities regulations. The content includes detailed descriptions of supervision work, compliance with laws and regulations, internal controls, information disclosure, risk monitoring, and other governance and operational oversight activities. It is not a full financial report like an annual or interim report but a regulatory continuous supervision report by the sponsor. The document is lengthy (15,000 characters) and contains substantive content rather than just an announcement or certification. This type of document is typical of a regulatory or supervisory report related to IPO follow-up and ongoing sponsor duties in China. It does not fit into categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is best classified under Regulatory Filings (RNS) as a general regulatory compliance and supervision report that does not fit other specific categories.
2023-08-31 Chinese
迈威生物第二届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolutions of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes the approval of the company's 2023 semi-annual report and a special report on the use of raised funds. The document states that the reports themselves are disclosed on the Shanghai Stock Exchange website and other media, indicating this document is an announcement of the meeting resolutions rather than the reports themselves. The document length is short (1166 characters), and it does not contain the actual financial data or detailed report content, only the meeting decisions and references to where the reports can be found. Therefore, this fits the category of Regulatory Filings (RNS) as a formal regulatory announcement of meeting resolutions and report approvals, not the reports themselves or their detailed content.
2023-08-28 Chinese
迈威生物独立董事关于第二届董事会第二次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on the company's second board meeting, specifically regarding a special report on the storage and actual use of raised funds for the first half of 2023. It references compliance with regulatory guidelines on fundraising management and confirms proper use of funds. The document is short (756 characters) and focuses on an opinion related to a specific agenda item rather than presenting full financial data or a comprehensive report. This fits best with a Capital/Financing Update (CAP) as it deals with fundraising and capital usage updates rather than a full financial report or audit.
2023-08-28 Chinese
迈威生物2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes financial statements, management analysis, and risk disclosures, which are characteristic of an Interim / Quarterly Report (IR). There is no indication that this is an annual report (10-K) or just an announcement of a report (RPA). Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.